Observational studyBMC pulmonary medicine2025
Clinical analysis of the efficacy of bronchial artery embolization with gelatin sponge in our hospital for cryptogenic hemoptysis: a single-center, retrospective, observational study.
Observational study in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The characteristics of upper lobe-origin hemoptysis: analysis based on 31 patients.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveHemoptysis is a life-threatening condition requiring urgent treatment. Bronchial artery embolization (BAE), established as the primary intervention, is an effective treatment for hemoptysis. Common etiologies include bronchiectasis, tumors, tuberculosis, aspergilloma, and cystic fibrosis. Approximately 20% of hemoptysis cases are categorized as cryptogenic. We conducted a retrospective observational study to understand the clinical characteristics of patients with cryptogenic hemoptysis (CH).
methodsThe clinical characteristics, angiographic findings, and immediate and long-term efficacies of BAE were retrospectively analyzed in 36 consecutive patients between January 2010 and December 2022. Superselective BAE was successfully performed in all patients by using a gelatin sponge (GS).
resultsThe median age was 68 years, and 21 patients (58.3%) were male. Among them, 15 patients (41.7%) presented with massive hemoptysis, and 7 (19.4%) required intubation. Angiographic evaluation revealed the treatment of total 57 vessels, comprising 51 (89.5%) bronchial arteries, 5 (8.8%) intercostal arteries, and 1 (1.8%) inferior transverse artery. The recurrence-free rates were 100% at 1 month, 94.4% at 3 months, 94.4% at 12 months, and 86.1% at more than 12 months. Only one patient required a second BAE for hemoptysis, while others were managed for recurrences with oral hemostatic agents. No serious complications, such as spinal cord infarction, were observed during the study period.
conclusionBAE treatment with GS for CH proved to be a suitable therapeutic modality, demonstrating high efficacy in halting bleeding in both the short and long terms, with the absence of severe complications, including spinal cord infarction.
trial registrationThis study was retrospectively registered for the UMIN Clinical Trial Registry (UMIN000042050) on October 8th, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.